- Home
- PTCT vs AXSM Comparison
PTCT vs AXSM Comparison
Compare PTCT & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTCT
- AXSM
- Stock Information
- Founded
- PTCT 1998
- AXSM 2012
- Country
- PTCT United States
- AXSM United States
- Employees
- PTCT N/A
- AXSM N/A
- Industry
- PTCT Biotechnology: Pharmaceutical Preparations
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- PTCT Health Care
- AXSM Health Care
- Exchange
- PTCT Nasdaq
- AXSM Nasdaq
- Market Cap
- PTCT 5.3B
- AXSM 5.9B
- IPO Year
- PTCT 2013
- AXSM 2015
- Fundamental
- Price
- PTCT $75.70
- AXSM $139.80
- Analyst Decision
- PTCT Buy
- AXSM Strong Buy
- Analyst Count
- PTCT 17
- AXSM 20
- Target Price
- PTCT $73.24
- AXSM $176.00
- AVG Volume (30 Days)
- PTCT 1.1M
- AXSM 545.5K
- Earning Date
- PTCT 11-04-2025
- AXSM 11-03-2025
- Dividend Yield
- PTCT N/A
- AXSM N/A
- EPS Growth
- PTCT N/A
- AXSM N/A
- EPS
- PTCT 8.94
- AXSM N/A
- Revenue
- PTCT $1,779,150,000.00
- AXSM $561,263,000.00
- Revenue This Year
- PTCT $119.02
- AXSM $63.66
- Revenue Next Year
- PTCT N/A
- AXSM $54.46
- P/E Ratio
- PTCT $8.42
- AXSM N/A
- Revenue Growth
- PTCT 97.54
- AXSM 65.83
- 52 Week Low
- PTCT $35.95
- AXSM $75.56
- 52 Week High
- PTCT $76.80
- AXSM $144.15
- Technical
- Relative Strength Index (RSI)
- PTCT 79.67
- AXSM 64.97
- Support Level
- PTCT $69.23
- AXSM $123.50
- Resistance Level
- PTCT $73.98
- AXSM $144.15
- Average True Range (ATR)
- PTCT 2.67
- AXSM 5.54
- MACD
- PTCT 0.40
- AXSM -0.03
- Stochastic Oscillator
- PTCT 89.08
- AXSM 78.50
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.